<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599219</url>
  </required_header>
  <id_info>
    <org_study_id>APR2016-27</org_study_id>
    <secondary_id>2016-A00117-44</secondary_id>
    <nct_id>NCT03599219</nct_id>
  </id_info>
  <brief_title>Platelet Dysfunction in Blood Donors</brief_title>
  <acronym>DysPlaq</acronym>
  <official_title>Prevalence of Platelet Dysfunction Inblood With a Bleeding History</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Etablissement Français du Sang</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelets are circulating blood cells. They bind to each other and to the damaged vessel wall
      to prevent excessive bllod loss. Unlike quantitative platelet defects, there is no automated,
      simple test to diagnose qualitative platelets defects. However, these defects expose to
      bleeding in a surgical situation and could explain the transfusion inefficiency of some
      platelet concentrates.

      In recent decades, considerable progress has been made in understanding qualitative platelet
      disorders.

      In this project, we propose to submit blood donors to a standardized hemorrhagic diathesis
      questionnaire and to compare the prevalence of platelet function abnormalities in blood
      donors with and without hemorrhagic diathesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective specify the prevalence of qualitative platelet disorders in blood donors
      with i) a clinical history of bleeding diathesis collected through a standardized and
      validated questionnaire ii) and / or a hematoma (more than 4 cm) that occurred during blood
      donation.

      Secondary objectives to obtain the prevalence of other defects of hemostasis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Anticipated">June 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective case control</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet functions</measure>
    <time_frame>first visit 1 week</time_frame>
    <description>Quantification of surface platelet proteins by flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploration of Coagulation</measure>
    <time_frame>first visit 1 week</time_frame>
    <description>Von Willebrand factor quantification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Platelet Dysfunction in Blood Donors</condition>
  <arm_group>
    <arm_group_label>case</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>donors with an hemorrhagic score &gt;2 and / or hematoma (more than 4 cm) that occurred during blood donation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>donors with an hemorrhagic score &lt;2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sample</intervention_name>
    <description>confirmation of platelet dysfunction</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>questionnary to obtain an hemorrhagic score</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Any male or female volunteer eligible for the blood donation

        Exclusion Criteria:

          -  Subject with contraindications to blood donation:

          -  weight &lt;50 kg;

          -  severe fatigue,

          -  anemia,

          -  insulin-dependent diabetes;

          -  subject treated for epileptic seizures or having followed a treatment whose arrest is
             less than 14 days old.

          -  active pregnancy or childbirth less than 6 months old.

          -  viral disease (eg influenza, gastroenteritis ...) active less than two weeks after the
             end of symptoms.

          -  waiting period not respected after certain acts of daily life according to the
             regulatory criteria set by the EFS

          -  HIV infection, hepatitis B, hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Picard Christophe, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Etablissement francais du sang</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiaroni Jacques, Professor</last_name>
    <phone>+ 33 (0) 491189557</phone>
    <email>jacques.chiaroni@efs.sante.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessi Marie-Christine, Professor</last_name>
    <phone>+33 (0) 4 91 32 45 06</phone>
    <email>marie-christine.alessi@univ-amu.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maison Du Don</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Picard, Dr</last_name>
      <phone>+33 (0) 491189596</phone>
      <email>christophe.picard@efs.sante.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelets</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Platelet Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

